



Baseline EPOS 2020 eligibility and real-world outcomes of dupilumab in CRSwNP


A longitudinal cohort study



Greater baseline disease burden in EPOS-eligible patients

TPS	-4.0	-3.0
SNOT-22	-37	-26
Sniffin' sticks	+4	+1

Dupilumab treatment effect



Response refinement

EPOS 2020 criteria provide a useful framework for dupilumab allocation in CRSwNP, while type 2 inflammatory features may further refine prediction of treatment response